BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716]
URL: https://www.wjgnet.com/1007-9327/full/v27/i44/7716.htm
Number Citing Articles
1
Chin-Chia Wu, Chuan-Yin Fang, Ben-Hui Yu, Chun-Ming Chang, Ta-Wen Hsu, Chung-Lin Hung, Shih-Kai Hung, Wen-Yen Chiou, Jui-Hsiu Tsai. Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal CancerCancers 2023; 15(21): 5304 doi: 10.3390/cancers15215304
2
Soo Hee Jeong, Lara Molloy, Edmond Ang, Nuala Helsby. Re-thinking the possible interaction between proton pump inhibitors and capecitabineCancer Chemotherapy and Pharmacology 2022; 90(5): 381 doi: 10.1007/s00280-022-04473-9
3
Elżbieta Wojaczyńska, Jacek Wojaczyński. Sulfoxides in medicineCurrent Opinion in Chemical Biology 2023; 76: 102340 doi: 10.1016/j.cbpa.2023.102340
4
Wan-Ying Lin, Shih-Syuan Wang, Yi-No Kang, Andrea S. Porpiglia, Yu Chang, Chin-Hsuan Huang, Ronak Bhimani, Eahab Abdul-Lattif, Muneeba Azmat, Tsu-Hsien Wang, Yu-Shiuan Lin, Yu-Cheng Chang, Kuan-Yu Chi. Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysisFrontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1048980
5
Khaled A. N. Abusharkh, Ferah Comert Onder, Venhar Çınar, Zuhal Hamurcu, Bulent Ozpolat, Mehmet Ay. A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cellsMedical Oncology 2024; 41(8) doi: 10.1007/s12032-024-02427-0
6
Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron, Véronique Lorgis, Véronique Guerin-Meyer, Vincent Bourgeois, David Malka, Thomas Aparicio, Matthieu Baconnier, Valérie Lebrun-Ly, Joëlle Egreteau, Faïza Khemissa Akouz, Magali Terme, Côme Lepage, Valérie Boige. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Cancers 2024; 16(8): 1515 doi: 10.3390/cancers16081515